Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The replacement mutation in HLA-DRB1*1211 affects a likely keystone position.

Peter A Horn1, David S DeLuca, Pavel Jindra

  • 1Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

Human Immunology
|May 13, 2006
PubMed
Summary

A new Human Leukocyte Antigen (HLA)-DRB1*12 allele, designated DRB1*1211, was identified. This discovery, stemming from a single nucleotide change, may significantly alter peptide binding and immune response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fundamentals of big data and artificial intelligence in transfusion medicine.

Vox sanguinis·2026
Same author

Exploring the effects of tinzaparin and cisplatin on lung cancer cells in vitro.

Cancer cell international·2026
Same author

A real-time dashboard for optimizing blood product utilization through a FHIR-based data integration pipeline.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party.

Cancers·2025
Same author

A Multimodal Pipeline for Clinical Data Extraction: Applying Vision-Language Models to Scans of Transfusion Reaction Reports.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Clinical lymphoma, myeloma & leukemia·2025

Area of Science:

  • Immunogenetics
  • Molecular Biology
  • Human Leukocyte Antigen (HLA) system

Background:

  • The HLA-DRB1*12 family comprises 10 known amino acid variants.
  • HLA alleles are crucial for immune system function and transplantation compatibility.

Purpose of the Study:

  • To report the identification and characterization of a novel HLA-DRB1*12 allele.
  • To investigate the potential functional impact of this new allele on peptide binding and immune recognition.

Main Methods:

  • Sequencing-based typing for high-resolution HLA typing.
  • Identification of nucleotide and amino acid substitutions.
  • Computational analysis of the structural and functional significance of the mutation.

Main Results:

Related Experiment Videos

  • A new HLA-DRB1*12 allele, designated DRB1*1211, was identified in a healthy Caucasian male.
  • The new allele differs from DRB1*120101 by a T-to-C mutation at nucleotide position 126 in exon 2, causing a Phe-to-Leu substitution at amino acid position 47.
  • Position 47 is critical for the structural conformation of the peptide binding groove and directly influences peptide binding.

Conclusions:

  • The novel HLA-DRB1*1211 allele possesses a unique amino acid substitution at a functionally significant position.
  • This alteration is predicted to modify the peptide-binding repertoire and alloreactive potential compared to other DRB1*12 alleles.
  • Further studies are warranted to fully elucidate the immunological implications of DRB1*1211.